Abstract: An MRI method is disclosed for the geometrical characterisation of pulmonary airways on the basis of a first tridimensional image of at least one bronchus of a bronchial tree and includes: acquiring a first MRI image, an MRI sequence being synchronised with a respiratory frequency; filtering the first image; segmenting a portion of the filtered image including the contours of the bronchial tree and its inner volumetric portion; estimating at least one plane of cut of a bronchus; generating at least one image slice of a bronchus; estimating, for each image slice, an area contained within the bronchial wall and/or a bronchial wall thickness.

Abstract: The invention relates to a method of assessing pregnancy outcome. The inventors investigated endometrial miRNAs associated with pregnancy outcome by studying miRNAs associated with endometrial receptivity, implantation failure and embryo miscarriage. They performed a miRNomic study to find miRNAs that are differentially expressed according to the endometrial receptivity status, compared the endometrial miRNome between receptive patients with negative beta-hCG and receptive patients with positive beta-hCG, and compared the endometrial miRNome between receptive patients with a miscarriage between 8-12 weeks of amenorrhoea and receptive patients with a live birth. They demonstrated miRNA differential expression in endometrial samples according to the pregnancy outcome.

Abstract: The invention describes a method for obtaining purified recombinant Adeno-Associated Virus particles (rAAV), comprising performing a depth filtration of a starting material previously obtained from cells producing rAAV particles comprising a cell lysate and/or a culture supernatant, followed by a first step of anion-exchange chromatography, a second step of anion-exchange chromatography and a final step of tangential flow filtration, whereby purified recombinant Adeno-Associated Virus particles (rAAV) are provided.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: The invention provides for a medical apparatus (100, 200, 300) for treating cells of a subject comprising at least one transducer (102, 224) with a vibrating surface (116). The transducer further comprises an applicator (118, 600) for attaching the vibrating surface to an outer surface of the subject (108, 218). The transducer is operable to vibrate at a frequency between 10 Hz and 1000 Hz. The medical apparatus further comprises a controller (104, 222, 230) for controlling the vibration of the transducer. The controller is operable for causing the transducer to vibrate for greater than a predetermined period of time for treating the cells. The predetermined period of time is greater than one hour.

Abstract: The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.

Abstract: The present invention is in the technical field of breast cancer management, and more particularly relates to the diagnosis of breast cancer. The invention is more particularly based on the finding that specific biomarkers (olfactomedin-4, neudesin and desmoplakin) are abberantly expressed in the blood of breast cancer patients.

Abstract: A computer-implemented method of characterizing molecular diffusion within a body from a set of diffusion-weighted magnetic resonance signals by computing a weighted average of a plurality of multi-compartment diffusion models comprises a same number of compartments, fitted to a set of diffusion-weighted magnetic resonance signals, the weighted average being computed using weights representative of a performance criterion of each of the models; wherein each of the multi-compartment diffusion models comprises a different number of subsets of compartments, the compartments of a same subset being identical to each other.

Abstract: The present invention relates to a method for recombinant production of a C1q protein or a variant of the C1q protein, in which the protein is recovered from an in vitro culture of cells expressing a C1qA subunit or a variant of the C1qA subunit, a C1qB subunit or a variant of the C1qB subunit, and a C1qC subunit or a variant of the C1qC subunit, in which at least one of the subunits or subunit variants also has at the N-terminus or C-terminus a sequence of amino acids of at least six residues, at least 40% of which are glutamic acid and/or aspartic acid residues.

Abstract: The present invention relates to a compound having formula (I): wherein: —X is in particular 125I Or 211At; —R1 and R?1 are independently from each other chosen preferably from the group consisting of electron-withdrawing groups and alkyl groups; —R2 is chosen from the group consisting of: H, alkyl groups, functional groups being able to bind a vector, and functional groups having targeting properties which make the compound of the invention a vector itself; —Z is a heteroatom, R5, R8 and R9 are preferably H; —Y is preferably an electron withdrawing group.

Abstract: Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.

Abstract: The present invention relates to the regulation of the activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity. The invention further relates to methods of screening for agonists or antagonists of NET in order to identify new pro-angiogenic or anti-angiogenic compounds and to therapeutic uses of these compounds. The invention also relates to transgenic animals bearing mutations in NET gene.

Abstract: An in vitro method for the obtention of a food- or auto-antigen specific Tr1 cell population from a leukocyte or a PBMC population, includes stimulating the PBMC or leukocyte population with the food- or auto-antigen, and recovering the food- or auto-antigen specific Tr1 cell population from the stimulated cell population. Preferably, the PBMC or leukocyte population is re-stimulated at least once with the same antigen after step (1), in the presence of IL-2 and at least one interleukin selected from the group consisting of IL-4 and IL-13. The in vitro method may further include a third step of expanding the recovered antigen-specific Tr1 cell population, advantageously by contacting them with feeder cells capable of expressing factors necessary for the expansion. Preferably, the feeder cells are recombinant insect feeder cells.

Abstract: The invention relates to a method for preparing antigen-specific Tr1 regulatory lymphocytes. The inventive method involves the use of artificial antigen-presenting cells, expressing a molecule from the HLA class II system and a human LFA-3 molecule and expressing none of the B7-1, B7-2, B7-H1, CD40, CD23 or ICAM-1 costimulation molecules.

Abstract: The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.

Abstract: The invention relates to a process for in vitro diagnosis of an infection by human cytomegaloviruses. The process consists of contacting cells, possibly carrying the infection, with a monoclonal antibody reacting with a polypeptide of molecular weight 68,000, induced by human cytomegalovirus and which possesses a protein-kinase activity. The detection of the reaction is preferably carried out by immunofluorescence.

Abstract: The invention relates to a process for in vitro diagnosis of an infection by human cytomegaloviruses. The process consists of contacting cells possibly carrying the infection, with a monoclonal antibody reacting with a polypeptide of molecular weight 68,000, induced by human cytomegalovirus and which possesses a protein-kinase activity. The detection of the reaction is preferably carried out by immunofluorescence.

Abstract: The present invention relates to methods for identifying and selecting compositions useful in differentially modulating the expression of two or more mammalian genes, particularly matrix metalloproteinase (MMP) genes such as those encoding interstitial collagenase (and other genes comprising an AP1-binding site) and stromelysin-3 (and other genes comprising a retinoic acid response element (RARE)). In addition, the invention relates to methods of treating a mammal (such as a human) suffering from or predisposed to a physical disorder, using pharmaceutical compositions comprising the compositions identified or selected by the above-described methods. The methods of the present invention are useful in treating a variety of physical disorders in mammals including cancers (particularly carcinomas), inflammatory disorders, fibrotic disorders, ocular disorders and osteoporosis.